Lead Product(s): OX40L monoclonal antibody
Therapeutic Area: Immunology Product Name: KY1005
Highest Development Status: Phase I Product Type: Large molecule
Deal Size: $1,450.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition April 09, 2021
Sanofi gains Kymab's KY1005 to its pipeline, a fully human monoclonal antibody targeting key immune system regulator OX40L. Kymab’s pipeline also includes the oncology asset KY1044.
Lead Product(s): NT-0167
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Novo Holdings
Deal Size: $55.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing June 03, 2020
Proceeds to support advancement of pipeline of small molecule NLRP3 inflammasome inhibitors, including continued progression of NT-0167 through clinical development.